• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Friday

    7/28/23 12:36:40 PM ET
    $AADI
    $ABVC
    $ADAP
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AADI alert in real time by email

     

    Friday's session saw 59 companies set new 52-week lows.

    Interesting Facts About Today's 52-Week Lows:

    • Bristol-Myers Squibb (NYSE:BMY) was the largest firm by market cap to set a new 52-week low.
    • BitNile Metaverse (NASDAQ:BNMV) was the smallest company in terms of market cap to set a new 52-week low.
    • Tonix Pharmaceuticals (NASDAQ:TNXP) saw the largest move of the companies, as shares plummetted 38.2% to hit a new 52-week low.
    • ClearPoint Neuro (NASDAQ:CLPT)'s stock bounced back the most, actually rising 0.0% after reaching its new 52-week low.

    The following stocks created new 52-week lows on Friday:

    • Bristol-Myers Squibb (NYSE:BMY) shares were up 0.07% for the day, having made a 52-week low of $60.05.
    • TC Energy (NYSE:TRP) shares were down 4.72% for the day, having made a 52-week low of $33.05.
    • Enphase Energy (NASDAQ:ENPH) shares were down 10.61% for the day, having made a 52-week low of $145.67.
    • Apellis Pharmaceuticals (NASDAQ:APLS) shares made a new 52-week low of $27.90 on Friday. The stock was down 5.79% for the day.
    • NovoCure (NASDAQ:NVCR) shares set a new 52-week low of $32.51. The stock traded down 2.86%.
    • Clearway Energy (NYSE:CWEN) stock hit a yearly low of $26.30. The stock was down 0.26% for the day.
    • TELUS Intl (NYSE:TIXT) shares set a new 52-week low of $9.31. The stock traded down 0.21%.
    • Impinj (NASDAQ:PI) stock hit a new 52-week low of $65.47. The stock was down 5.13% on the session.
    • Maravai LifeSciences (NASDAQ:MRVI) stock broke to a new 52-week low of $11.12 on Friday. Shares of the company traded up 0.39%.
    • Baijiayun Group (NASDAQ:RTC) shares fell to $6.29 on Friday, setting a new 52-week low with a shift of up 3.69%.
    • 2seventy bio (NASDAQ:TSVT) stock achieved a new 52-week low on Friday morning, hitting $7.46 and moving down 7.08%.
    • Emergent BioSolutions (NYSE:EBS) shares set a new 52-week low of $6.72. The stock traded up 0.87%.
    • TPI Composites (NASDAQ:TPIC) shares reached a new 52-week low of $5.56 on Friday morning, moving down 6.52%.
    • Prelude Therapeutics (NASDAQ:PRLD) stock hit $3.96 on Friday morning, setting a new 52-week low for a change of down 3.12%.
    • Rimini Street (NASDAQ:RMNI) stock set a new 52-week low of $2.26 on Friday, moving down 2.33%.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) shares moved up 2.56% on Friday to hit a new 52-week low of $0.87, drifting up 2.56%.
    • NGM Biopharmaceuticals (NASDAQ:NGM) stock drifted down 0.44% on Friday morning to hit a new 52-week low of $2.23.
    • Nouveau Monde Graphite (NYSE:NMG) stock set a new 52-week low of $2.73 on Friday, moving down 4.83%.
    • Complete Solaria (NASDAQ:CSLR) shares set a new yearly low of $3.50 this morning. The stock was down 1.87% on the session.
    • ClearPoint Neuro (NASDAQ:CLPT) shares set a new 52-week low of $6.25. The stock traded 0.0% (flat).
    • Electrovaya (NASDAQ:ELVA) stock set a new 52-week low of $4.11 on Friday, moving down 3.17%.
    • NioCorp Developments (NASDAQ:NB) stock hit $4.35 on Friday morning, setting a new 52-week low for a change of up 1.37%.
    • Aadi Bioscience (NASDAQ:AADI) stock hit a yearly low of $5.17. The stock was down 3.35% for the day.
    • G1 Therapeutics (NASDAQ:GTHX) stock set a new 52-week low of $2.31 on Friday, moving up 1.29%.
    • Eargo (NASDAQ:EAR) shares hit a yearly low of $3.88. The stock was up 2.31% on the session.
    • MSP Recovery (NASDAQ:LIFW) stock hit a new 52-week low of $0.20. The stock was up 10.04% on the session.
    • CEL-SCI (AMEX:CVM) shares hit a yearly low of $1.53. The stock was down 9.94% on the session.
    • Delta Apparel (AMEX:DLA) shares reached a new 52-week low of $8.71 on Friday morning, moving down 0.4%.
    • Airgain (NASDAQ:AIRG) stock hit a new 52-week low of $4.61. The stock was down 2.71% on the session.
    • Leap Therapeutics (NASDAQ:LPTX) stock set a new 52-week low of $2.26 on Friday, moving up 5.79%.
    • Phoenix New Media (NYSE:FENG) stock hit a yearly low of $1.63. The stock was down 6.78% for the day.
    • Strong Global (AMEX:SGE) shares hit a yearly low of $2.40. The stock was up 2.0% on the session.
    • Addentax Group (NASDAQ:ATXG) shares made a new 52-week low of $3.42 on Friday. The stock was down 0.83% for the day.
    • Tonix Pharmaceuticals (NASDAQ:TNXP) shares made a new 52-week low of $1.01 on Friday. The stock was down 38.2% for the day.
    • Golden Minerals (AMEX:AUMN) shares moved down 3.88% on Friday to hit a new 52-week low of $1.20, drifting down 3.88%.
    • China Jo-Jo Drugstores (NASDAQ:CJJD) shares set a new yearly low of $0.36 this morning. The stock was down 0.5% on the session.
    • Precipio (NASDAQ:PRPO) stock hit a new 52-week low of $0.31. The stock was down 0.25% on the session.
    • ABVC BioPharma (NASDAQ:ABVC) stock hit a yearly low of $2.61. The stock was down 14.19% for the day.
    • Powerbridge Technologies (NASDAQ:PBTS) stock drifted down 5.04% on Friday morning to hit a new 52-week low of $0.26.
    • Siyata Mobile (NASDAQ:SYTA) shares set a new 52-week low of $0.04. The stock traded down 7.05%.
    • Applied UV (NASDAQ:AUVI) stock drifted down 2.37% on Friday morning to hit a new 52-week low of $0.80.
    • TRACON Pharma (NASDAQ:TCON) shares fell to $0.26 on Friday, setting a new 52-week low with a shift of down 3.18%.
    • Micromobility com (NASDAQ:MCOM) stock hit a new 52-week low of $0.07. The stock was down 7.85% on the session.
    • FOXO Technologies (AMEX:FOXO) stock drifted up 0.89% on Friday morning to hit a new 52-week low of $0.13.
    • Lixte Biotech Hldgs (NASDAQ:LIXT) stock dropped to a yearly low on Friday of $3.23. Shares traded down 7.61%.
    • Bellerophon Therapeutics (NASDAQ:BLPH) stock set a new 52-week low of $0.39 on Friday, moving down 3.71%.
    • Adamis Pharmaceuticals (NASDAQ:ADMP) shares were down 7.41% for the day, having made a 52-week low of $1.45.
    • Ault Alliance (AMEX:AULT) stock set a new 52-week low of $2.78 on Friday, moving down 1.68%.
    • C3is (NASDAQ:CISS) stock hit $0.55 on Friday morning, setting a new 52-week low for a change of up 2.42%.
    • EBET (NASDAQ:EBET) shares set a new 52-week low of $0.08. The stock traded down 0.29%.
    • Gaucho Group Holdings (NASDAQ:VINO) shares set a new 52-week low of $0.48. The stock traded down 3.92%.
    • Kiromic BioPharma (NASDAQ:KRBP) stock hit a yearly low of $2.46. The stock was down 3.68% for the day.
    • Avalo Therapeutics (NASDAQ:AVTX) shares set a new 52-week low of $0.18. The stock traded down 9.71%.
    • G Medical Innovations (NASDAQ:GMVD) shares were down 14.96% for the day, having made a 52-week low of $0.27.
    • Ucommune International (NASDAQ:UK) shares set a new 52-week low of $0.33. The stock traded down 4.81%.
    • Esports Entertainment (NASDAQ:GMBL) shares made a new 52-week low of $0.41 on Friday. The stock was down 1.49% for the day.

    Be sure to monitor Benzinga for the news traders need! And for even more up-to-date info on 52-week lows and highs, check out Benzinga Pro. This cutting-edge market research platform alerts traders of which stocks are trading near their 52-week highs and lows each morning - and delivers lots of other actionable data. Learn more here.

    Get the next $AADI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AADI
    $ABVC
    $ADAP
    $ADMP

    CompanyDatePrice TargetRatingAnalyst
    TC Energy Corporation
    $TRP
    4/23/2026Neutral → Sector Outperform
    CIBC
    TC Energy Corporation
    $TRP
    4/20/2026$62.00Sell → Neutral
    Goldman
    Avalo Therapeutics Inc.
    $AVTX
    4/9/2026$48.00Outperform
    Wolfe Research
    Avalo Therapeutics Inc.
    $AVTX
    4/6/2026$52.00Mkt Outperform
    Citizens
    Apellis Pharmaceuticals Inc.
    $APLS
    3/13/2026$31.00Buy
    Roth Capital
    Bristol-Myers Squibb Company
    $BMY
    2/25/2026$60.00Sector Perform
    RBC Capital Mkts
    Enphase Energy Inc.
    $ENPH
    2/25/2026$57.00Hold → Buy
    Jefferies
    Bristol-Myers Squibb Company
    $BMY
    2/20/2026$75.00Overweight
    Barclays
    More analyst ratings

    $AADI
    $ABVC
    $ADAP
    $ADMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TC Energy upgraded by CIBC

    CIBC upgraded TC Energy from Neutral to Sector Outperform

    4/23/26 11:56:01 AM ET
    $TRP
    Natural Gas Distribution
    Utilities

    TC Energy upgraded by Goldman with a new price target

    Goldman upgraded TC Energy from Sell to Neutral and set a new price target of $62.00

    4/20/26 8:21:38 AM ET
    $TRP
    Natural Gas Distribution
    Utilities

    Wolfe Research initiated coverage on Avalo Therapeutics with a new price target

    Wolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00

    4/9/26 8:40:45 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ABVC
    $ADAP
    $ADMP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ABVC
    $ADAP
    $ADMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bonita David P bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/23/26 6:50:38 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/23/26 6:48:25 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Kothandaraman Badrinarayanan bought $259,884 worth of shares (5,000 units at $51.98) (SEC Form 4)

    4 - Enphase Energy, Inc. (0001463101) (Issuer)

    2/5/26 4:41:25 PM ET
    $ENPH
    Semiconductors
    Technology

    $AADI
    $ABVC
    $ADAP
    $ADMP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

    Expands Options for Cash-Paying Patients to Access the Nation's #1 Prescribed Oral Blood Thinner The Bristol Myers Squibb-Pfizer (NYSE:BMY) — (NYSE:PFE) Alliance today announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to offer Eliquis® (apixaban) on CostPlusDrugs.com. Eliquis is one of the most widely prescribed oral anticoagulants in the United States and one of the largest brands in the space to be offered on the site, which allows patients to purchase prescription medicines directly at reduced costs, providing another avenue for patients to access the medication. "The BMS-Pfizer Alliance is pleased to expand our direct-to-patient options

    4/24/26 6:59:00 AM ET
    $BMY
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    C3is Inc. Announces Reverse Stock Split

    To be effective April 27, 2026 Aiming to meet the minimum bid price requirement for maintaining listing on Nasdaq ATHENS, Greece, April 23, 2026 (GLOBE NEWSWIRE) -- C3is Inc. (the "Company") (NASDAQ:CISS) today announced that its board of directors has determined to effect a one-for-seven (1-for-7) reverse stock split of the Company's common stock, par value $0.01 per share. The reverse stock split will take effect at 11:59 pm Eastern Time on April 26, 2026, and the Company's common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market ("Nasdaq") as of the opening of trading on April 27, 2026. The CUSIP number of Y18284300 will be assigned to the Company's com

    4/23/26 8:30:00 AM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

    SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv

    4/23/26 8:00:00 AM ET
    $BMY
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ABVC
    $ADAP
    $ADMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bonita David P bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/23/26 6:50:38 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/23/26 6:48:25 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Baker Bros. Advisors Lp

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/22/26 4:15:58 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ABVC
    $ADAP
    $ADMP
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Prelude Therapeutics Incorporated

    SCHEDULE 13D/A - Prelude Therapeutics Inc (0001678660) (Subject)

    4/23/26 8:42:51 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by ClearPoint Neuro Inc.

    DEFA14A - ClearPoint Neuro, Inc. (0001285550) (Filer)

    4/23/26 5:08:22 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by C3is Inc.

    6-K - C3is Inc. (0001951067) (Filer)

    4/23/26 4:15:10 PM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    $AADI
    $ABVC
    $ADAP
    $ADMP
    Leadership Updates

    Live Leadership Updates

    View All

    Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

    WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W. Ettenberg, a seasoned leader with more than 25 years of legal experience in the biopharmaceutical industry, as Chief Legal Officer (CLO). She will oversee Ardelyx's legal, compliance, regulatory, and government affairs operations. Ms. Ettenberg succeeds Elizabeth Grammer, who has chosen to retire after an extraordinary 16-year career at the company. "I am thrilled to welcome Felecia as our new Chief Legal Officer," said Mik

    4/20/26 8:00:00 AM ET
    $ARDX
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

    WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude Therapeutics" or the "Company"), a clinical-stage precision oncology company, today announced that Dr. Charles Morris will join the Company as Chief Medical Officer effective, April 20, 2026. "We are thrilled to welcome Dr. Charles Morris to Prelude Therapeutics as Executive Vice President and Chief Medical Officer," stated Kris Vaddi, Chief Executive Officer of Prelude Therapeutics. "With our two lead programs targeting myeloproliferative neoplasms and ER+ breast cancer advancing expected to enter into clinical development in 2026, Dr. Morris's deep clinical experience, track re

    4/15/26 7:30:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Airgain® Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Airgain, Inc. (NASDAQ:AIRG), a leading provider of advanced wireless connectivity solutions, today announced that it has granted inducement awards to two new employees who recently joined the Company. The awards were granted on March 15, 2026, under Airgain's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Airgain as an inducement to join the company. The inducement awards to the new employees consist in the aggregate of options to purchase 24,000 shares of Airgain common stock and 1,000 restricted stock units ("RSUs"). The options have a 10-year term and an exercise price equal to $4.02, the fair market value of Airg

    3/18/26 5:57:00 PM ET
    $AIRG
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $AADI
    $ABVC
    $ADAP
    $ADMP
    Financials

    Live finance-specific insights

    View All

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

    SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv

    4/23/26 8:00:00 AM ET
    $BMY
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026

    Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2026 financial and operating results after the market close on Thursday, May 7, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-5172 or 1-203-518-9856 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com. About Maravai Maravai is a leading li

    4/20/26 4:05:00 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

    GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can b

    4/16/26 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ABVC
    $ADAP
    $ADMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care